Table 1 Cumulative clinical manifestations, autoantibody panels, initial creatine phosphokinase serum levels, and comorbidities of the patients with antisynthetase syndrome
Antisynthetase syndrome | n = 64 |
|---|---|
Cumulative clinical manifestations | |
Muscle involvement | 61 (95.3) |
Joint involvement | 59 (92.2) |
Lung involvement | 57 (89.1) |
Ground-glass | 46 (71.9) |
Incipient pneumopathy | 40 (62.5) |
Pulmonary fibrosis | 14 (21.9) |
Pulmonary nodules | 11 (17.2) |
“Mechanic’s hands” | 57 (89.1) |
Raynaud’s phenomenon | 50 (78.1) |
Fever | 46 (71.9) |
Autoantibody panels | |
Antinuclear factor | 52 (81.3) |
Anti-Ro-52 | 28 (43.8) |
Anti-tRNA aminoacyl transferase | 64 (100.0) |
Anti-Jo-1 | 52 (81.3) |
Anti-PL-12, anti-PL-7 or anti-EJ | 12 (18.7) |
Anti-OJ | 0 |
Initial creatine phosphokinase (U/L) | 3015 (632–8463) |
Comorbidities | |
Systemic arterial hypertension | 22 (34.4) |
Diabetes mellitus | 12 (18.8) |
Hypothyroidism | 3 (4.7) |
Acute myocardial infarction | 3 (4.7) |
Stroke | 1 (1.6) |